Zurich, Switzerland – August 1st, 2022 – Navignostics is delighted to welcome Christin Zündorf to the growing team as part of her secondment for the coming months. Christin will take on the role of business and commercial expert to tackle strategic questions around the company’s go-to-market model and to provide support to create first value streams.
Christin brings a strong business skillset from her experience in strategy consulting into the Navignostics team. In the past years, she supported Pharmaceutical- and MedTech clients with various questions around commercial excellence, portfolio strategy, launch planning and digital health. She brings broad expertise across the healthcare industry, but has a deep focus on precision medicine in oncology. With her academic background in Management & Technology (Chemistry) from Technical University of Munich, she complements the founding team’s capabilities.
Christin is looking forward to contributing to Navignostics’ mission to make personalized medicine a reality for cancer patients: « Every second person will eventually develop some form of cancer in their lives. Treatment pathways are still standardized and don’t offer the best treatment options. I am looking forward to personalizing cancer treatments with a novel diagnostic technology approach at Navignostics!
Navignostics is a spin-off company from the University of Zurich, founded in April 2022, which is leveraging spatial single-cell proteomics to perform advanced analyses of tumor samples. As a start–up active in the personalized medicine field, Navignostics strives to provide innovative solutions to identify the best possible treatment for each cancer patient. In addition, Navignostics provides advanced services to pharmaceutical companies to accelerate cancer drug development and to contribute to companion diagnostic development.